OncoMatch/Clinical Trials/NCT06916767
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Is NCT06916767 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including BAFF CAR-T and Obinutuzumab for relapsed cll.
Treatment: BAFF CAR-T · Obinutuzumab · Cyclophosphamide · Fludarabine — CAR-T cell treatment of refractory lymphoma has shown success, particularly with CD-19 targeted CAR-T cells, however, many participants are refractory or relapse after response. Responses are more limited in CLL/SLL, possibly secondary to the suppressive effect of circulating B cells on T cell function. BAFF receptor is a target that has been explored in CLL. Preclinical data indicates that CAR- T cells expressing B-cell activating factor (BAFF) can be another effective strategy to treat refractory CLL. This study aims to explore the efficacy of LMY-920 a BAFF-ligand CAR T cells with depletion of B cells with Obinutuzumab prior to apheresis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: BTK inhibitor
Relapsed after 2 or more lines of therapy, including a BTK inhibitor
Must have received: BCL2 inhibitor
Relapsed after 2 or more lines of therapy, including a BCL2 inhibitor
Cannot have received: autologous stem cell transplant
ASCT within 6 weeks of informed consent
Cannot have received: allogeneic hematopoietic stem cell transplantation
History of allogeneic hematopoietic stem cell transplantation
Cannot have received: investigational agent
Less than 28 days elapsed between prior treatment with investigational agent(s) and the day of lymphocyte collection
Lab requirements
Kidney function
calculated creatinine clearance ≥ 30ml/min.
Liver function
total bilirubin ≤ 1.5 x upper institutional limit of normal (except in participants with gilbert's syndrome, active hemolysis or disease involvement of the liver). ast (sgot)/alt ≤ 2.5 x institutional upper limit of normal.
Cardiac function
cardiac ejection fraction of ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify